Mainz, Germany: A grey and gloomy day by the river Rhine has been brightened up by the quality of science on display at the 2019 annual meeting of the Association for Cancer Immunotherapy (CIMT) (Twitter: #CIMT2019).
We were last here in Mainz 18 months ago for the EACR-CIMT-AACR Immuno-Oncology conference.
Cancer immunotherapy remains a work in progress, however.
What’s increasingly becoming more important is understanding the science, in particular finding answers to critical “why” questions that help us to not only understand the biology of cancer, but also why some people respond and others don’t.
In this post, we describe some of the key highlights and have penned some thoughts on some of the oral talks and posters presented today.